Progressive research of Alzheimer's disease-related blood markers

doi:10.3969/j.issn.1673-8640.2020.04.019

Abstract

Abstract:

Alzheimer's disease（AD）is a degenerative disease of the central nervous system with clinical manifestations of memory impairment,cognitive impairment,later personality and behavioral changes. Recently,studies have shown that many blood markers are closely related to AD,like protein,gene mutation,microRNA（miRNA）,which may play a certain role in predicting the risk of AD,reflecting the stage of AD and supporting the diagnosis of AD. In addition,the determination method of blood markers is simple and easy,therefore screening ideal AD-related blood markers is beneficial to the screening and treatment of AD. In this review,the latest research status of AD-related blood markers is summarized,and the possibility and limitation of its clinical application are discussed.

Key words: Blood marker, Alzheimer's disease, Screening, Diagnosis

CLC Number:

R446.1

CHEN Xiaotong, LIN Yong. Progressive research of Alzheimer's disease-related blood markers[J]. Laboratory Medicine, 2020, 35(4): 374-379.

References 50.

1.	SUGINO H,WATANABE A,AMADA N,et al.Global trends in alzheimer disease clinical development:increasing the probability of success[J]. Clin Ther,2015,37(8):1632-1642.
2.	FRICKER M,TOLKOVSKY A M,BORUTAITE V,et al.Neuronal cell death[J]. Physiol Rev,2018,98(2):813-880.
3.	DUBOIS B,FELDMAN H H,JACOVA C,et al.Research criteria for the diagnosis of Alzheimer's disease:revising the NINCDS-ADRDA criteria[J]. Lancet Neurol,2007,6(8):734-746.
4.	DUBOIS B,FELDMAN H H,JACOVA C,et al.Advancing research diagnostic criteria for Alzheimer's disease:the IWG-2 criteria[J]. Lancet Neurol,2014,13(6):614-629.
5.	JACK C R Jr,BENNETT D A,BLENNOW K,et al. NIA-AA research framework:toward a biological definition of Alzheimer's disease[J]. Alzheimers Dement,2018,14(4):535-562.
6.	JAGUST W.Imaging the evolution and pathophysiology of Alzheimer disease[J]. Nat Rev Neurosci,2018,19(11):687-700.
7.	SCHELTENS P,BLENNOW K,BRETELER M M,et al.Alzheimer's disease[J]. Lancet,2016,388(10043):505-517.
8.	WANG J,GU B J,MASTERS C L,et al.A systemic view of Alzheimer disease-insights from amyloid-β metabolism beyond the brain[J]. Nat Rev Neurol,2017,13(10):612-623.
9.	VERBERK I M W,SLOT R E,VERFAILLIE S C J,et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes[J]. Ann Neurol,2018,84(5):648-658.
10.	NAKAMURA A,KANEKO N,VILLEMAGNE V L,et al.High performance plasma amyloid-β biomarkers for Alzheimer's disease[J]. Nature,2018,554(7691):249-254.
11.	NABERS A,PERNA L,LANGE J,et al.Amyloid blood biomarker detects Alzheimer's disease[J]. EMBO Mol Med,2018,10(5).
12.	VARMA V R,OOMMEN A M,VARMA S,et al.Brain and blood metabolite signatures of pathology and progression in Alzheimer disease:a targeted metabolomics study[J]. PLoS Med,2018,15(1):e1002482.
13.	SHEN Y,WANG H,SUN Q,et al.Increased plasma beta-secretase 1 may predict conversion to Alzheimer's disease dementia in individuals with mild cognitive impairment[J]. Biol Psych,2018,83(5):447-455.
14.	PEÑA-BAUTISTA C,VIGOR C,GALANO J M,et al. Plasma lipid peroxidation biomarkers for early and non-invasive Alzheimer disease detection[J]. Free Radic Biol Med,2018,124:388-394.
15.	TROUGAKOS I P.The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress:implications in therapeutic approaches-a mini-review[J]. Gerontology,2013,59(6):514-523.
16.	PERROTTE M,LE PAGE A,FOURNET M,et al.Blood-based redox-signature and their association to the cognitive scores in MCI and Alzheimer's disease patients[J]. Free Radic Biol Med,2019,130:499-511.
17.	PADURARIU M,CIOBICA A,HRITCU L,et al.Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease[J]. Neurosci Lett,2010,469(1):6-10.
18.	HEPPNER F L,RANSOHOFF R M,BECHER B.Immune attack:the role of inflammation in Alzheimer disease[J]. Nat Rev Neurosci,2015,16(6):358-372.
19.	HENEKA M T,GOLENBOCK D T,LATZ E.Innate immunity in Alzheimer's disease[J]. Nat Immunol,2015,16(3):229-236.
20.	FORLENZA O V,DINIZ B S,TALIB L L,et al.Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment[J]. Dement Geriatr Cogn Disord,2009,28(6):507-512.
21.	HARDY J,SELKOE D J.The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics[J]. Science,2002,297(5580):353-356.
22.	HEILIG E A,XIA W,SHEN J,et al.A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity[J]. J Biol Chem,2010,285(29):22350-22359.
23.	VEUGELEN S,SAITO T,SAIDO T C,et al.Familial Alzheimer's disease mutations in presenilin generate amyloidogenic Aβ peptide seeds[J]. Neuron,2016,90(2):410-416.
24.	WANG Y,MANDELKOW E.Tau in physiology and pathology[J]. Nat Rev Neurosci,2016,17(1):5-21.
25.	MIELKE M M,HAGEN C E,XU J,et al.Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography[J]. Alzheimers Dement,2018,14(8):989-997.
26.	OLSSON B,LAUTNER R,ANDREASSON U,et al.CSF and blood biomarkers for the diagnosis of Alzheimer's disease:a systematic review and meta-analysis[J]. Lancet Neurol,2016,15(7):673-684.
27.	CORSI M M,LICASTRO F,PORCELLINI E,et al.Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease:relationship with neuro-degeneration[J]. Biogerontology,2011,12(5):451-454.
28.	丁冰玉,林萍,李擎天. 植物血凝素刺激外周血单个核细胞Th1/Th2细胞因子分泌对阿尔茨海默病的诊断价值[J]. 检验医学,2018,33(4):290-294.
29.	D'ANNA L,ABU-RUMEILEH S,FABRIS M,et al. Serum interleukin-10 levels correlate with cerebrospinal fluid amyloid beta deposition in Alzheimer disease patients[J]. Neurodegener Dis,2017,17(4-5):227-234.
30.	TOGO T,AKIYAMA H,KONDO H,et al.Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases[J]. Brain Res,2000,885(1):117-121.
31.	MOCALI A,CEDROLA S,DELLA MALVA N,et al.Increased plasma levels of soluble CD40,together with the decrease of TGF beta 1,as possible differential markers of Alzheimer disease[J]. Exp Gerontol,2004,39(10):1555-1561.
32.	BROSSERON F,KRAUTHAUSEN M,KUMMER M,et al.Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease:a comparative overview[J]. Mol Neurobiol,2014,50(2):534-544.
33.	TRAMUTOLA A,ABATE G,LANZILLOTTA C,et al.Protein nitration profile of CD3+:lymphocytes from Alzheimer disease patients:novel hints on immunosenescence and biomarker detection[J]. Free Radic Biol Med,2018,129:430-439.
34.	BHATNAGAR S,CHERTKOW H,SCHIPPER H M,et al.Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma[J]. Front Mol Neurosci,2014,7:2.
35.	AYBEK H,ERCAN F,ASLAN D,et al.Determination of malondialdehyde,reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli,Turkey[J]. Clin Biochem,2007,40(3-4):172-176.
36.	FIANDACA M S,KAPOGIANNIS D,MAPSTONE M,et al.Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes:a case-control study[J]. Alzheimers Dement,2015,11(6):600-607.e1.
37.	HARA N,KIKUCHI M,MIYASHITA A,et al.Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease[J]. Acta Neuropathol Commun,2017,5(1):10.
38.	YANG T T,LIU C G,GAO S C,et al.The serum exosome derived microRNA-135a,-193b,and -384 were potential Alzheimer's disease biomarkers[J]. Biomed Environ Sci,2018,31(2):87-96.
39.	HONG S,BEJA-GLASSER V FNFONOYIM B M,et al.Complement and microglia mediate early synapse loss in Alzheimer mouse models[J]. Science,2016,352(6286):712-716.
40.	ZHOU X,CHEN Y,MOK K Y,et al.Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer's disease pathogenesis[J]. Proc Natl Acad Sci U S A,2018,115(8):1697-1706.
41.	WENDELN A C,DEGENHARDT K,KAURANI L,et al.Innate immune memory in the brain shapes neurological disease hallmarks[J]. Nature,2018,556(7701):332-338.
42.	SNYDER H M,CARRILLO M C,GRODSTEIN F,et al.Developing novel blood-based biomarkers for Alzheimer's disease[J]. Alzheimers Dement,2014,10(1):109-114.
43.	FIORINI M,BONGIANNI M,BENEDETTI M D,et al.Reappraisal of Aβ40 and Aβ42 peptides measurements in cerebrospinal fluid of patients with Alzheimer's disease[J]. J Alzheimers Dis,2018,66(1):219-227.
44.	SWEENEY M D,SAGARE A P,ZLOKOVIC B V.Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders[J]. Nat Rev Neurol,2018,14(3):133-150.
45.	HENRIKSEN K,O'BRYANT S E,HAMPEL H,et al. The future of blood-based biomarkers for Alzheimer's disease[J]. Alzheimers Dement,2014,10(1):115-131.
46.	THAMBISETTY M,LOVESTONE S.Blood-based biomarkers of Alzheimer's disease:challenging but feasible[J]. Biomark Med,2010,4(1):65-79.
47.	O'BRYANT S E,EDWARDS M,JOHNSON L,et al. A blood screening test for Alzheimer's disease[J]. Alzheimer's Dementia(Amst),2016,3:83-90.
48.	WOOD H.Alzheimer disease:localized proteomics distinguishes AD subtypes[J]. Nat Rev Neurol,2017,13(5):260.
49.	ROSENBERG R N,LAMBRACHT-WASHINGTON D,YU G,et al.Genomics of Alzheimer disease:a review[J]. JAMA Neurol,2016,73(7):867-874.
50.	XIANG Y,LAM S M,SHUI G.What can lipidomics tell us about the pathogenesis of Alzheimer disease?[J]. Biol Chem,2015,396(12):1281-1291.

[1]	WANG Huiying, TANG Yu, DONG Lili, WANG Jing. Role of Mycoplasma pneumoniae RNA determination in diagnosis and efficacy monitoring of pneumonia in children [J]. Laboratory Medicine, 2023, 38(9): 865-869.
[2]	SUN Xinlin, YE Xingming, LI Qian, ZHAO Lijun. Bronchoscopy combined with sputum Mycobacterium tuberculosis ribonucleic acid and serum Mycobacterium tuberculosis specific antibody determinations for diagnosis of negative pulmonary tuberculosis [J]. Laboratory Medicine, 2023, 38(9): 870-873.
[3]	HAN Xue, WEN Liu, WAN Yang. Analysis of amniotic fluid chromosome karyotype and genome copy number variation in critical or high-risk pregnant women by Down's screening [J]. Laboratory Medicine, 2023, 38(6): 548-552.
[4]	ZHANG Chu, WANG Jianhong, LI Rui, XIAO Yanhua, WANG Heng, ZHANG Pinxiao, XU Ningxin, XIA Banban. Results of non-invasive prenatal testing-plus in 5 696 pregnant women [J]. Laboratory Medicine, 2023, 38(6): 553-558.
[5]	ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598.
[6]	LI Xijiu, ZHOU Jianwei, ZHANG Qin, LONG Yunlin, WU Yingsong. Establishment and performance evaluation of UPLC-MS/MS for 6 markers in dried blood spots [J]. Laboratory Medicine, 2023, 38(5): 446-453.
[7]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Roles of serum HYAL1 and HA in the auxiliary diagnosis and therapeutic monitoring of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 313-319.
[8]	YU Tingting, WANG Jian. Progress and challenges in diagnosis and treatment of rare diseases [J]. Laboratory Medicine, 2023, 38(2): 103-105.
[9]	CAI Xiaoyi, LOU Dan, YANG Xingge, WANG Jian. Genetic analysis on 15 cases of suspected Duchenne muscular dystrophy/Becker muscular dystrophy [J]. Laboratory Medicine, 2023, 38(2): 106-111.
[10]	WANG Dongjiang, GUO Jian. Advance in laboratory diagnosis of invasive fungal infection [J]. Laboratory Medicine, 2023, 38(2): 179-185.
[11]	WEN Jing, SHI Rui, XIE Jia, LIU Feng, LI Guang, REN Jingjing, LEI Xiaoru, GUO Xiaobo, SONG Yanping. Clinical application of metagenomic next-generation sequencing for determining pathogens in febrile neutropenic patients [J]. Laboratory Medicine, 2022, 37(9): 855-859.
[12]	XU Qi, PAN Fen, SUN Yan, SHI Yingying, YU Fangyuan, ZHANG Hong. Methodology evaluation of screening techniques for CRE colonized in intestinal tract [J]. Laboratory Medicine, 2022, 37(8): 761-765.
[13]	SUN Lei, LONG Ju, FAN Zuqian, WU Suping, LIN Guixian, LING Xiuming. sRapid determination of sex chromosome abnormality using double relative quantitative SD-qPCR [J]. Laboratory Medicine, 2022, 37(6): 557-560.
[14]	GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312.
[15]	JI Wei, TIAN Guoli, ZHU Zhixing, ZHOU Zhuo, WANG Yanmin, ZHANG Xiaofen. Feasibility of indirect method to establish the cut-off value of neonatal G6PD screening in Shanghai [J]. Laboratory Medicine, 2022, 37(2): 112-116.